Stem Cell Dosage, Cell Counts and Quality: How to Read the Numbers

Why cell count became the headline number

Look at regenerative clinic marketing and you will notice how quickly the conversation turns to numbers. Fifty million cells. A hundred million. Two hundred million. The implication is straightforward: more cells, better result, and therefore this clinic is superior to the one down the road offering fewer.

There is a reason this number does so much marketing work. It is concrete, comparable and impressive-sounding in a field where most of what matters is hard for a patient to evaluate. You cannot easily assess laboratory standards, physician skill or sourcing integrity from a website. You can compare fifty million to a hundred million instantly. It functions much like megapixels once did in camera marketing — a real specification that correlates loosely with quality and correlates strongly with sales.

The problem is that the number is easy to state and hard to verify, is measured in ways that are not standardized across providers, and describes only one dimension of a product whose value depends on several. This article is about what the number means, what it omits, and what to ask instead. Our article on cell sources is a useful companion, since source and dose interact.

What is actually being counted

The first question worth asking is deceptively simple: what exactly are you counting? Preparations differ enormously in what the headline figure refers to. In bone marrow aspirate concentrate, the total nucleated cell count includes a great many cells that are not mesenchymal stem cells at all — the actual MSC fraction is typically a very small proportion of the total. A clinic quoting total nucleated cells is quoting a much bigger and much less relevant number than one quoting characterized MSCs.

Similarly, adipose-derived preparations may report cells in the stromal vascular fraction, which is a mixed population containing MSCs alongside other cell types. Cord-derived products may report cultured, characterized MSCs, which is a more specific figure. Comparing these numbers across preparations is close to meaningless without knowing what each includes.

Then there is viability — the proportion of cells that are actually alive and functional at the point of administration. A hundred million cells at low viability may deliver fewer functional cells than fifty million at high viability. Viability depends on processing, storage, transport and thawing technique, all invisible on a price list. A clinic that reports both count and viability, and can say how viability was measured, is operating at a higher standard than one that reports a single impressive figure.

Potency, purity and the things that resist marketing

Beyond count and viability sits potency, which is the hardest concept to market and arguably the most important. Two preparations with identical cell counts and viability can differ in functional capability — how effectively the cells secrete the anti-inflammatory and signaling factors that are thought to drive the therapeutic effect. Potency is influenced by donor characteristics, culture conditions, passage number and handling.

Passage number deserves a mention because it is rarely discussed with patients. Cultured cells are expanded through successive passages, and cells at higher passage numbers may show reduced functional capacity even while remaining viable and countable. A large number produced through extensive expansion is not equivalent to the same number at lower passage.

Purity and characterization matter too: whether the population has been characterized against accepted surface marker criteria for mesenchymal stem cells, and whether the product has been tested for contamination. None of this appears in a headline figure, and none of it is something a patient can see. It is, however, something a patient can ask about — and the quality of the answer is informative in itself.

Is more actually better?

The intuitive assumption is a straight dose-response relationship: more cells, more effect. The honest answer is that this has not been established for most indications, and the relationship may not be linear. Some research suggests thresholds below which effect is unlikely and above which additional cells add little. Some suggests different optimal doses for different routes of delivery and different targets. What does not exist is a settled, agreed dosing standard across the field.

That absence is itself worth noticing. In established pharmacology, dosing is determined through systematic study, and a drug's label specifies it precisely. The fact that regenerative medicine has no equivalent consensus for most applications is one of the clearest indicators that many of these uses remain investigational rather than standardized, as discussed in our evidence and safety guide.

There is also a practical caution. Unusually high advertised cell counts, particularly at prices notably below market, should invite questions rather than confidence. Producing large quantities of well-characterized, high-viability cells requires laboratory capability that is expensive. A number that seems too good relative to price is a reason to ask harder questions about what is being counted and how — not a bargain to seize.

Delivery: the variable nobody advertises

Here is a factor that outweighs modest differences in cell count and receives almost no marketing attention: whether the cells reach the intended location. For targeted orthopedic treatment, this is the difference between an image-guided injection placing material precisely into the degenerative region of a tendon or into a specific joint compartment, and a blind injection that approximates.

In small structures — the plantar fascia, the tendons around the shoulder, the ankle joint — the difference between guided and unguided delivery is substantial, and a technically excellent biologic delivered to the wrong tissue does nothing regardless of how many cells it contained. Our articles on shoulder treatment and foot and ankle treatment both make this point, because it matters more than dosage in those settings.

For systemic intravenous administration the considerations differ, but the underlying principle holds: how the product is handled, thawed and administered affects how much functional material actually arrives. A clinic focused on advertising counts while saying nothing about guidance technique or handling protocol has chosen the marketable variable over the consequential one.

What to ask, and how to weigh the answers

A short list of questions cuts through most of this. What exactly are you counting — total nucleated cells, stromal vascular fraction, or characterized MSCs? What is the viability at administration, and how is it measured? What passage number are cultured cells at? How has the product been characterized and tested for contamination? How will it be delivered, and will image guidance be used? Will you document all of this in writing?

Weigh the answers less on the numbers themselves and more on the quality of the response. A provider who can explain what they measure, how, and why they chose a particular dose for your situation is demonstrating exactly the competence that matters. A provider who repeats a large number and deflects the follow-up questions has told you where their attention goes.

At HealthBridge, our medical director Dra. Olga González leads the longevity and regenerative program, and all therapies are administered by licensed physicians under Colombian regulations following individualized assessment. We think patients are poorly served by being encouraged to shop on cell count, because it turns a clinical decision into a specification comparison and rewards whoever states the biggest number. The more useful comparison is which provider will tell you plainly what they are giving you, why that dose, and what they expect it to do — including when the honest answer is that the evidence for a given indication is investigational. Our pillar guide to stem cell therapy in Colombia covers the science behind these decisions.